Update
$Achilles Therapeutics (ACHL.US)$ Achilles Therapeutics Provides Interim Phase 1/2a Update on Clonal Neoantigen Reactive T Cells In Advanced NSCLC And Melanoma Including First Patients Dosed With Enhanced Host Conditioning
Moomoo 24/7· 1 min ago
Achilles Therapeutics (ACHL.Improved VELOS manufacturing process delivering higher cNeT doses.
Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024.
First three patients dosed in CHIRON and THETIS with enhanced host chemo-conditioning, along with IL-2 aligned to standard TIL therapy, show improved cNeT persistence and engraftment.
Moomoo 24/7· 1 min ago
Achilles Therapeutics (ACHL.Improved VELOS manufacturing process delivering higher cNeT doses.
Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024.
First three patients dosed in CHIRON and THETIS with enhanced host chemo-conditioning, along with IL-2 aligned to standard TIL therapy, show improved cNeT persistence and engraftment.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
